Rapport Therapeutics, Inc. - 8-K Filing

Rapport Therapeutics announced positive Phase 2 trial results for RAP-219 in treating bipolar mania on October 20, 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 20, 2026, 10:06 UTC

Tickers: $RAPP

Read the full article at SEC EDGAR

More Regulatory news

Carter Bankshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:12 UTC
Marvell Technology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
VISHAY INTERTECHNOLOGY INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
LATTICE SEMICONDUCTOR CORP - 4 Filing SEC EDGAR · November 12, 2026, 14:10 UTC
CENTRUS ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:09 UTC
SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC